On the Charterhouse Square Campus, the School aims to deliver an internationally recognised centre of excellence in Cardiovascular and Cancer research, which will directly complement the clinical service delivery on the St Bartholomew’s Hospital site.
Three Institutes are based in Charterhouse Square:
- the Barts Cancer Institute;
- the William Harvey Research Institute, majoring in cardiovascular research, genetics, pharmacology and endocrinology;
- and the Wolfson Institute of Preventive Medicine, majoring in molecular epidemiology and public health.
The William Harvey Research Institute offers a vibrant, fully integrated clinical and basic science environment devoted to understanding basic pathogenic mechanisms and therapeutic innovation in cardiovascular, inflammatory and endocrine diseases.
Since 2001 William Harvey investigators have published in high impact journals such as Nature, Nature Genetics, Nature Biotechnology, The Lancet, Circulation, Journal of Experimental Medicine and the Journal of Immunology, and spent over £33 million on research. These successes have led to the William Harvey being ranked amongst the top 20 pharmacological research institutions in the world based upon citations (according to The Scientist, 2004).
Barts Cancer Institute
Barts Cancer Institute was founded in 2003 (as the Institute of Cancer) and under the leadership of Professor Nick Lemoine has rapidly developed into one of the leading centres in Europe. In Spring 2004 the School launched a Cancer Research-UK Clinical Centre on this campus, the first CR-UK clinical centre in the UK. In 2007 it hosted, in collaboration with the University of Cambridge, the CR-UK Molecular Pathology Training Programme. Also in 2007, with funding from the Department of Health, the Institute was awarded £2 million to establish the first Experimental Cancer Medicine Centre, to fast-track new cancer treatments. It is led by Professor John Gribben and Professor Nick Lemoine. In 2011 the Institute of Cancer was renamed Barts Cancer Institute.
Wolfson Institute of Preventive Medicine
The Wolfson Institute of Preventive Medicine at Charterhouse Square houses some of the most renowned figures in public health worldwide. Led by Professor Sir Nicholas Wald FRS, it has produced ground-breaking research on screening for Down’s syndrome, the role of folate in the prevention of spina bifida, and the ability of the “polypill” to reduce dramatically cardiovascular disease and stroke.
The Cancer Epidemiology group, led by Professor Jack Cuzick, is a world leader in cancer prevention and among its achievements is showing that breast screening reduces mortality from breast cancer. The John Vane Building which houses most of the research staff at Charterhouse Square has undergone complete modernisation in the last 3 years, and a new Heart Centre, which will focus on various elements of cardiovascular disease, from the use of stem cells in the treatment of heart attacks, to better understanding the disorders of heart rhythm that affect 10% of the elderly population, aims to start activity in October 2010.
On the Whitechapel Campus, a new landmark architecturally distinguished building for research into cell and molecular science opened in April 2005 (the Blizard Building). This exciting capital development houses the Blizard Institute for Cell and Molecular Science (ICMS), with laboratory and office accommodation for 400 research workers in disciplines which match the local clinical activities of The Royal London Hospital.
The ICMS includes research centres of excellence in Skin Disease, Immunology and Infectious Disease, Gastroenterology, Surgery, Paediatrics, Diabetes and Neurosciences. A key feature of the design of the new build is the large open-plan laboratory and office accommodation which aims to ensure maximum flexibility and interaction between the research workers of the ICMS. A key element of the School’s investment strategy for this Institute is to encourage inter-disciplinary research through the development of themes which link multiple centres and thereby gain synergistic value.
Another major development at Whitechapel is the QM Bioenterprises building, scheduled to open in 2009, adjacent to the Blizard Building, which will provide 40,000 square feet of space for small to medium bioscience companies. This will be available for QM researchers wishing to commercialise their research as well as those from other institutions. An exciting feature of this development is the webbased portal which will allow prospective clients and entrepeneurs to design and cost facilities on-line.
The School is also redeveloping other sites to house the Centre for Health Sciences, to drive forward our primary care research agenda in the unique health care setting of east London, with its large immigrant communities.